AstraZeneca plc (AZN) Receives Hold Rating from Jefferies Group LLC

Jefferies Group LLC restated their hold rating on shares of AstraZeneca plc (LON:AZN) in a research report report published on Thursday morning, MarketBeat.com reports. Jefferies Group LLC currently has a GBX 5,100 ($67.08) price objective on the biopharmaceutical company’s stock.

A number of other equities analysts also recently issued reports on AZN. Investec increased their price target on AstraZeneca plc from GBX 4,900 ($64.45) to GBX 5,500 ($72.34) and gave the stock a buy rating in a research report on Monday, November 6th. J P Morgan Chase & Co set a GBX 4,200 ($55.24) price target on AstraZeneca plc and gave the stock a neutral rating in a research report on Wednesday, August 9th. Barclays PLC reissued an overweight rating and set a GBX 5,500 ($72.34) price target on shares of AstraZeneca plc in a research report on Monday, August 7th. HSBC Holdings PLC raised their price objective on AstraZeneca plc from GBX 4,340 ($57.08) to GBX 4,380 ($57.61) and gave the company a reduce rating in a research report on Thursday. Finally, UBS AG set a GBX 4,550 ($59.84) price objective on AstraZeneca plc and gave the company a neutral rating in a research report on Thursday, November 9th. Four research analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have assigned a buy rating to the company’s stock. The company has an average rating of Hold and a consensus target price of GBX 5,150.82 ($67.75).

AstraZeneca plc (LON:AZN) opened at GBX 4,957 ($65.20) on Thursday. AstraZeneca plc has a 52-week low of GBX 49.50 ($0.65) and a 52-week high of GBX 5,520 ($72.60).

TRADEMARK VIOLATION WARNING: “AstraZeneca plc (AZN) Receives Hold Rating from Jefferies Group LLC” was first published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this article on another website, it was illegally copied and reposted in violation of US & international copyright and trademark law. The original version of this article can be accessed at https://sportsperspectives.com/2017/11/20/astrazeneca-plc-azn-receives-hold-rating-from-jefferies-group-llc.html.

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply